Laboratory Corp. of America (NYSE:LH) had its target price boosted by Morgan Stanley from $175.00 to $190.00 in a report published on Friday morning, BenzingaRatingsTable reports. They currently have an overweight rating on the medical research company’s stock.

Several other research analysts have also issued reports on LH. Wolfe Research assumed coverage on Iqvia in a research report on Tuesday, April 2nd. They set a market perform rating on the stock. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a buy rating in a research report on Monday, July 15th. Jefferies Financial Group reaffirmed a sell rating on shares of Hi-Crush Partners in a research report on Tuesday, April 2nd. Mizuho set a $31.00 target price on Evolus and gave the company a buy rating in a research report on Monday, May 20th. Finally, Canaccord Genuity reaffirmed a buy rating and set a $10.00 target price on shares of Chembio Diagnostics in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $183.54.

Shares of LH traded down $5.24 during trading hours on Friday, hitting $166.53. The company had a trading volume of 1,475,967 shares, compared to its average volume of 642,381. The company has a market cap of $16.92 billion, a P/E ratio of 15.11, a PEG ratio of 1.57 and a beta of 1.04. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.12 and a quick ratio of 1.05. Laboratory Corp. of America has a one year low of $119.38 and a one year high of $182.75. The business’s fifty day moving average price is $171.74.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Thursday, July 25th. The medical research company reported $2.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.90 by $0.03. The firm had revenue of $2.88 billion during the quarter, compared to analyst estimates of $2.89 billion. Laboratory Corp. of America had a return on equity of 16.28% and a net margin of 8.19%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.98 EPS. Sell-side analysts predict that Laboratory Corp. of America will post 11.29 earnings per share for the current year.

In other Laboratory Corp. of America news, CFO Glenn A. Eisenberg sold 10,000 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $167.40, for a total transaction of $1,674,000.00. Following the sale, the chief financial officer now owns 28,366 shares in the company, valued at approximately $4,748,468.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Robert E. Mittelstaedt, Jr. sold 3,700 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $166.30, for a total value of $615,310.00. Following the sale, the director now owns 18,909 shares in the company, valued at approximately $3,144,566.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,191 shares of company stock worth $4,948,144. Company insiders own 0.74% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Osborn Williams & Donohoe LLC purchased a new stake in Laboratory Corp. of America during the 1st quarter valued at about $32,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Laboratory Corp. of America in the second quarter worth about $32,000. Legacy Advisors LLC purchased a new stake in shares of Laboratory Corp. of America in the second quarter worth about $33,000. Bremer Bank National Association purchased a new stake in shares of Laboratory Corp. of America in the first quarter worth about $35,000. Finally, Shine Investment Advisory Services Inc. boosted its stake in shares of Laboratory Corp. of America by 30.7% in the first quarter. Shine Investment Advisory Services Inc. now owns 277 shares of the medical research company’s stock worth $42,000 after buying an additional 65 shares during the last quarter. Institutional investors and hedge funds own 91.48% of the company’s stock.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Article: Net Margin – Understanding the Different Kinds of Profit

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.